With
Alison Hayman,
Cameron Mingay,
Frank Robinson,
Jonathan Sherman
Colorado Governor Jared Polis signed House Bill 1090 (the "Bill") on Wednesday May 29, 2019, which opened up Colorado's cannabis industry to outside investors for the first time.
With
Alison Hayman
The Federal Cannabis Act (the "Act") establishes restrictions and exceptions for those looking to advertise and market Cannabis in Canada.
The "use" requirement will be eliminated.
With
Michael Britton,
Rowan Groenewald,
Alison Hayman,
Jonathan Sherman,
Michael Weizel
October 17, 2018, marks a historic day in the evolution of cannabis regulations both domestically and abroad.
With
Noble C. Chummar,
Tegan O'Brien,
Hon. David R. Peterson, P.C., Q.C.,
Brenda C. Swick
After lengthy and intense negotiation, the North American Free Trade Agreement (NAFTA) has been reintroduced as the United States-Mexico-Canada Agreement (USMCA), the new tri-party trade...
Health Canada is soliciting input on possible changes to the Food and Drug Regulations regarding establishing pharmaceutical equivalence between a proposed generic drug product and the Canadian Reference Product.
The new CSP system provides an additional period of patent-like protection for patentees after the date of expiry of certain eligible pharmaceutical patents.
The Supreme Court of Canada's (the "Court" or the "SCC") recent judgment in AstraZeneca Canada Inc. v Apotex Inc., released on June 30, 2017, constitutes an important paradigm shift in Canadian patent law.
On May 16, 2017, the Federal Minister of Health, the Hon. Jane Philpott announced a number of proposed regulatory changes to the Patented Medicines Regulations (the "Regulations").
Under the Patent Act in Canada, an invention must be new and useful to be patentable.
In Apotex Inc. v Canada (Minister of Health) ("Apotex"), the Federal Court (the "Court") provided some guidance with respect to the procedure pharmaceutical companies should undertake...
The Federal Court has reaffirmed and clarified how a pharmaceutical brand company should respond to a generic company's motion to strike an application for abuse of process...
With
Emily Larose
Health Canada has recently released the revised Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs, replacing the March 2010 Guidance for Sponsors...
Based on Mondaq users readership, this author is ranked as Very Popular in Canada for the topics, user groups and industry sectors listed below:
Industry
Pharmaceuticals & BioTechLaw Firm* Rankings are based on analysis of the last 12 months of Mondaq readership data across more than 25,000 contributing authors. To be ranked ‘Very Popular’ an author must be in the top 20% of results within the selected criteria.
